专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

21. 发明申请

US20190076581A1 CATIONIC STEROIDAL ANTIBIOTIC COMPOSITIONS FOR THE TREATMENT OF DERMAL TISSUE 审中-公开
公开(公告)号：US20190076581A1
公开(公告)日：2019-03-14
申请号：US16184211
申请日：2018-11-08
申请人： Paul B. Savage , Carl Genberg , Ronald Bracken
发明人： Paul B. Savage , Carl Genberg , Ronald Bracken
IPC分类号： A61L27/54 , A61L24/00 , A61L27/58 , C08L5/08 , A61L27/22 , A61K31/575 , A61L27/16 , A61L27/18 , A61L24/08 , C08L83/04 , A61L24/04 , C08L67/04 , A61L24/06 , C08L33/12 , C08L35/04 , A61L26/00 , A61L24/10 , A61L27/50 , A61L27/24 , A61L27/20
摘要： This disclosure relates to dermal treatment compositions, such as dermal fillers and tissue glues, and injectable compositions that incorporate one or more cationic steroidal antimicrobials (CSAs). The CSAs are incorporated into the dermal treatment compositions to provide effective antimicrobial, anti-inflammatory, analgesic, anti-swelling and/or tissue-healing properties. A treatment composition includes a component formed from a biologically compatible material suitable for injection into and/or application onto tissue at a treatment site. One or more CSA compounds are mixed with the biologically compatible material so that the one or more CSA compounds are incorporated within the composition, forming a reservoir of CSA compounds within the resulting bolus of the treatment composition after injection and/or application.

22. 发明授权

US10220045B2 Compositions and methods for forming stabilized compositions with reduced CSA agglomeration 有权
公开(公告)号：US10220045B2
公开(公告)日：2019-03-05
申请号：US14642905
申请日：2015-03-10
申请人： Benjamin J. Darien , Paul B. Savage
发明人： Benjamin J. Darien , Paul B. Savage
IPC分类号： A61K9/16 , A61K9/48 , A61K31/575 , A61K9/14 , B06B1/00 , A61K31/56
摘要： Compositions and methods for preparing stabilized CSA compositions having reduced agglomeration and increased stability. The compositions have increased efficacy in killing microbes and reduced cytotoxicity to mammals. The compositions include a liquid carrier, micelles formed from an amphiphilic material, and CSA molecules encapsulated by the micelles. The CSA compositions can be formed by blending together a solvent or liquid carrier, a plurality of CSA molecules, and a micelle-forming agent and causing or allowing the micelle-forming agent to form micelles encapsulating at least a portion of the CSA molecules so that no more than 25% of the CSA molecules form agglomerates larger than 1 μm in size. The CSA compositions can be used to treat mammals, such as mammals suffering from microbial diseases or infections.

23. 发明申请

US20180169114A1 METHODS FOR REDUCING CELLULAR PROLIFERATION AND TREATING CERTAIN DISEASES 审中-公开
公开(公告)号：US20180169114A1
公开(公告)日：2018-06-21
申请号：US15895848
申请日：2018-02-13
申请人： Carl Genberg , Paul B. Savage
发明人： Carl Genberg , Paul B. Savage
IPC分类号： A61K31/575 , A61K31/56
CPC分类号： A61K31/575 , A61K31/56
摘要： Disclosed herein are methods of treating cancer and/or reducing cellular proliferation in a patient, comprising identifying a patient in need of treatment and administering a therapeutically effective amount of at least one cationic steroid antimicrobial (CSA), or a pharmaceutically acceptable salt thereof. Kits comprising such compositions and instructions on such methods are also contemplated herein.

24. 发明授权

US09943529B2 Methods for reducing cellular proliferation and treating certain diseases 有权
公开(公告)号：US09943529B2
公开(公告)日：2018-04-17
申请号：US14149675
申请日：2014-01-07
申请人： Carl Genberg , Paul B. Savage
发明人： Carl Genberg , Paul B. Savage
IPC分类号： A61K31/575 , A61K31/56
CPC分类号： A61K31/575 , A61K31/56
摘要： Disclosed herein are methods of treating cancer and/or reducing cellular proliferation in a patient, comprising identifying a patient in need of treatment and administering a therapeutically effective amount of at least one cationic steroid antimicrobial (CSA), or a pharmaceutically acceptable salt thereof. Kits comprising such compositions and instructions on such methods are also contemplated herein.

25. 发明授权

US09867836B2 Lavage and/or infusion using CSA compounds for increasing fertility in a mammal 有权
公开(公告)号：US09867836B2
公开(公告)日：2018-01-16
申请号：US14644946
申请日：2015-03-11
申请人： Chad S. Beus , Paul B. Savage
发明人： Chad S. Beus , Paul B. Savage
IPC分类号： A61K31/575 , A61K9/00
CPC分类号： A61K31/575 , A61K9/0017
摘要： Increasing fertility in a mammal utilizes cationic steroidal antimicrobial (CSA) compounds and CSA-containing compositions. Such treatment in a mammal includes administering a formulation (e.g., lavage and/or infusion) including at least one CSA compound, or pharmaceutically acceptable salt thereof, to the reproductive structure(s) of the mammal (e.g., horse, dairy cow, human, etc.). The formulation may be applied topically as lavage and/or infusion to desired reproductive structures, such as the vagina, cervix, uterus, penis, or combinations thereof. The formulation may kill both planktonic and biofilm forms of sperm killing microbes, and may at least partially break up a microbial plaque or film located within any of the reproductive structures (e.g., the uterus). The CSA or pharmaceutically acceptable salt thereof may be selective or preferential in its action, so as to preferentially kill sperm killing microbes without causing harm to beneficial microbes also residing within the reproductive structure of the mammal.

26. 发明申请

US20170232004A1 METHODS FOR TREATING FUNGAL INFECTIONS 审中-公开
公开(公告)号：US20170232004A1
公开(公告)日：2017-08-17
申请号：US15585632
申请日：2017-05-03
申请人： Carl Genberg , Chad S. Beus , Paul B. Savage
发明人： Carl Genberg , Chad S. Beus , Paul B. Savage
IPC分类号： A61K31/575 , A61K9/00 , A61K45/06
CPC分类号： A61K31/575 , A61K9/0014 , A61K45/06
摘要： Disclosed herein are methods of treating fungal infections in a patient, comprising identifying a patient in need of treatment and administering a therapeutically effective amount of at least one cationic steroid antimicrobial (CSA), or a pharmaceutically acceptable salt thereof. Kits comprising such compositions and instructions on such methods are also contemplated herein.

27. 发明授权

US09546195B2 Hydrophobic ceragenin compounds and devices incorporating same 有权
标题翻译：疏水性ceragenin化合物和结合相同的装置
公开(公告)号：US09546195B2
公开(公告)日：2017-01-17
申请号：US14602499
申请日：2015-01-22
申请人： Paul B. Savage
发明人： Paul B. Savage
IPC分类号： A61K31/56 , A61F13/00 , C07J51/00 , C07J41/00 , A61L27/52 , A61L27/54 , A61L31/14 , A61L31/16 , A61L27/34 , A61L29/08 , A61L29/14 , A61L29/16 , A61L31/10 , C07C211/00 , A61L27/18
CPC分类号： C07J41/0055 , A61L27/14 , A61L27/18 , A61L27/34 , A61L27/52 , A61L27/54 , A61L29/04 , A61L29/085 , A61L29/145 , A61L29/16 , A61L31/04 , A61L31/10 , A61L31/145 , A61L31/16 , A61L2300/208 , A61L2300/404 , A61L2300/606 , C07C211/00
摘要： A hydrophobic cationic steroidal anti-microbial (ceragenin) compound forms an amphiphilic compound having a hydrophobic sterol face and a hydrophilic cationic face. The hydrophobic CSA also includes a hydrophobic substituent that gives the ceragenin compound a C Log P value of at least 6.0, 6.25, 6.5, 7.5, 8.5, or 10.
摘要翻译：疏水性阳离子甾族抗微生物（ceragenin）化合物形成具有疏水性固醇面和亲水性阳离子面的两亲性化合物。疏水性CSA还包括疏水性取代基，其给予cerornin化合物的C Log P值至少为6.0,6.25,6.5,7.5,8.5或10。

28. 发明申请

US20160311850A1 CATIONIC STEROIDAL ANTIMICROBIAL SALTS 审中-公开
标题翻译：阳离子灭菌抗菌素
公开(公告)号：US20160311850A1
公开(公告)日：2016-10-27
申请号：US15135928
申请日：2016-04-22
申请人： Paul B. Savage , Saurabh Shashikant Chitre , Kunal Arvind Varia , Hayley Ann Reece , Thomas E. Jacks , Ross A. Miller , Jared Lynn Randall
发明人： Paul B. Savage , Saurabh Shashikant Chitre , Kunal Arvind Varia , Hayley Ann Reece , Thomas E. Jacks , Ross A. Miller , Jared Lynn Randall
IPC分类号： C07J41/00 , C07C309/29 , C07C309/35
CPC分类号： C07J41/0088 , C07B2200/13 , C07C309/29 , C07C309/35 , C07J41/0061
摘要： Disclosed herein are acid addition salts of cationic steroidal antimicrobials (“CSAs” or “ceragenins”) and methods of making the same. Particularly advantageous salt forms are identified, such as 1,5-naphthalenedisulfonic acid addition salts and sulfate addition salts. The acid addition salts may be formulated for treating subjects with ailments responsive to CSAs, including but not limited to treating bacterial infections. Accordingly, some embodiments include formulations and methods of administering acid addition salts of CSAs.
摘要翻译：本文公开了阳离子甾族抗微生物剂（“CSA”或“ceragenins”）的酸加成盐及其制备方法。确定了特别有利的盐形式，例如1,5-萘二磺酸加成盐和硫酸盐加成盐。可以将酸加成盐配制用于治疗对CSA有反应性疾病的受试者，包括但不限于治疗细菌感染。因此，一些实施方案包括施用CSA的酸加成盐的制剂和方法。

29. 发明授权

US09387215B2 Animal feed including cationic cholesterol additive and related methods 有权
标题翻译：动物饲料包括阳离子胆固醇添加剂及相关方法
公开(公告)号：US09387215B2
公开(公告)日：2016-07-12
申请号：US14257776
申请日：2014-04-21
申请人： Chad S. Beus , Paul B. Savage
发明人： Chad S. Beus , Paul B. Savage
IPC分类号： A61K31/575 , A23K1/165 , A23K1/16 , A23K1/18
CPC分类号： A61K31/575 , A23K20/10 , A23K20/168 , A23K50/10 , A23K50/20 , A23K50/30 , A23K50/45 , A23K50/75 , A23V2002/00 , A23V2200/32
摘要： Methods and feed compositions for increasing health of agricultural animals include administering a cationic cholesterol additive through the diet of the animal, such as through solid feed or drinking water of the animals. The method includes feeding an animal a diet comprised of a cationic cholesterol additive, such as a compound with a sterol backbone and a plurality of cationic groups attached thereto. The feed composition may include a solid or liquid feed component and a cationic cholesterol additive. The methods and compositions are useful for animals raised in confined feed operations, such as cattle, swine, horses, sheep, or poultry, and can reduce harmful bacteria in the digestive tract, increase beneficial bacteria flora, improve feed conversion efficiency, reduce morbity and/or mortality, and/or yield harvested meat having reduced content of harmful bacteria.
摘要翻译：用于增加农业动物健康的方法和饲料组合物包括通过动物的饮食施用阳离子胆固醇添加剂，例如通过动物的固体饲料或饮用水。该方法包括向动物喂食由阳离子胆固醇添加剂（例如化合物与固醇骨架）和多个连接到其上的阳离子基团组成的饮食。饲料组合物可以包括固体或液体进料组分和阳离子胆固醇添加剂。这些方法和组合物可用于在限制饲料操作中饲养的动物，例如牛，猪，马，羊或家禽，并且可以减少消化道中的有害细菌，增加有益的细菌菌群，提高饲料转化效率，降低发病率 /或死亡率，和/或产生具有降低的有害细菌含量的收获肉。

30. 发明申请

US20160096864A1 CATIONIC STEROIDAL ANTIMICROBIAL PRODRUG COMPOSITIONS AND USES THEREOF 审中-公开
标题翻译：阳离子类固醇抗微生物制剂组合物及其用途
公开(公告)号：US20160096864A1
公开(公告)日：2016-04-07
申请号：US14875953
申请日：2015-10-06
申请人： Paul B. Savage
发明人： Paul B. Savage
IPC分类号： C07J41/00 , A61K45/06 , A61K31/575
CPC分类号： C07J41/0055 , A61K31/575 , A61K45/06 , C07J41/0061 , C07J41/0094
摘要： Prodrugs or pharmaceutically acceptable salts, stereoisomers, solvates, or polymorphs thereof include a pharmaceutically and/or diagnostically active cationic steroidal antimicrobial (hereinafter “CSA”) compound or pharmaceutically acceptable salt, stereoisomer, solvate, or polymorph thereof, and one or more cleavable groups (C.G.). Some embodiments include a CSA compound prepared in an inactive or less active form and that is capable of conversion to a fully active form upon administration to a subject, upon preparation of a pharmaceutical formulation containing the CSA composition, and/or upon exposure to physiological conditions. Pharmaceutical compositions include the prodrug or pharmaceutically acceptable salt, stereoisomer, solvate, or polymorph thereof and one or more pharmaceutically acceptable excipients. Methods of treatment of bacterial infections in a patient in need utilize prodrugs or pharmaceutically acceptable salts, stereoisomers, solvates, polymorphs thereof and/or the pharmaceutical compositions described herein.
摘要翻译：前药或其药学上可接受的盐，立体异构体，溶剂化物或多晶型物包括药学上和/或诊断上活性的阳离子甾族抗微生物（以下称为“CSA”）化合物或其药学上可接受的盐，立体异构体，溶剂合物或其多晶型物，以及一个或多个可切割基团（CG）。一些实施方案包括以无活性或较低活性形式制备的CSA化合物，并且在制备含有CSA组合物的药物制剂时和/或在暴露于生理条件下时，能够在给予受试者时转化为完全活性形式。药物组合物包括前药或其药学上可接受的盐，立体异构体，溶剂合物或其多晶型物和一种或多种药学上可接受的赋形剂。在需要的患者中治疗细菌感染的方法使用本文所述的前药或其药学上可接受的盐，立体异构体，溶剂合物，多晶型物和/或药物组合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式